Tumor necrosis factor receptor superfamily member 11B; tumor necrosis factor receptor superfamily, member 11b; MGC29565; MGC93568; OCIF; OPG; Osteoclastogenesis inhibitory factor; Osteoprotegerin; TNFRSF 11B; TNFRSF11B; TR 1; TR1; TR11B_HUMAN; Tumor necrosis factor receptor superfamily member 11B

For Research Use Only. Not for use in diagnostic procedures.

Natural and recombinant Human OPG

Store at 4 degree C for 6 months, at -20 degree C for 12 months. Avoid multiple freeze-thaw cycles (Shipped with wet ice.)

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual.

Small volumes of TNFRSF11B elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS175881 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the OPG (TNFRSF11B) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing TNFRSF11B. The ELISA analytical biochemical technique of the MBS175881 kit is based on TNFRSF11B antibody-TNFRSF11B antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect TNFRSF11B antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, TNFRSF11B. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).

Principle of the Assay: Human OPG ELISA Kit was based on standard sandwich enzyme-linked immune-sorbent assay technology. A monoclonal antibody from mouse specific for OPG has been precoated onto 96-well plates. Standards(Expression system for standard: NSO; Immunogen sequence: E22-L401) and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for OPG is added subsequently and then followed by washing with PBS or TBS buffer. Avidin- Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the Human OPG amount of sample captured in plate.

Background: Osteoprotegerin(OPG) is identical to osteoclastogenesis inhibitory factor(OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation. Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system. The standard product used in this kit is recombinant OPG, a 55KDa glycoprotein.

46,026 Da

tumor necrosis factor receptor superfamily, member 11b

tumor necrosis factor receptor superfamily member 11B; osteoprotegerin; osteoclastogenesis inhibitory factor

Tumor necrosis factor receptor superfamily member 11B

OCIF; OPG??[Similar Products]

TR11B_HUMAN

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. This protein specifically binds to its ligand, osteoprotegerin ligand, both of which are key extracellular regulators of osteoclast development. Studies of the mouse counterpart also suggest that this protein and its ligand play a role in lymph-node organogenesis and vascular calcification. Alternatively spliced transcript variants of this gene have been reported, but their full length nature has not been determined. [provided by RefSeq, Jul 2008]

TNFRSF11B: Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD); also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast- mediated skeletal resorption, the disease can be fatal.

Protein type: Secreted, signal peptide; Inhibitor; Secreted

Chromosomal Location of Human Ortholog: 8q24

Cellular Component: extracellular space; proteinaceous extracellular matrix; extracellular region

Molecular Function: cytokine activity; receptor activity

Biological Process: response to drug; extracellular matrix organization and biogenesis; response to magnesium ion; apoptosis; negative regulation of odontogenesis of dentine-containing teeth; response to estrogen stimulus; response to arsenic; signal transduction; negative regulation of bone resorption; skeletal development; response to nutrient

Disease: Paget Disease, Juvenile

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.